|Bid||0.000 x 5800|
|Ask||0.000 x 143900|
|Day's Range||2.340 - 2.475|
|52 Week Range||1.810 - 7.445|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Measuring Epigenomics AG’s (DB:ECX) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceed expectations,Read More...
Legislation Aims to Provide Coverage Under the Medicare Program for FDA-approved Qualifying Colorectal Cancer Screening Blood-Based Tests BERLIN, GERMANY and GERMANTOWN, MD / ACCESSWIRE / March 8, 2018 ...
Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Epigenomics AG. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Epigenomics AG reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Epigenomics AG – Evotec AG, WILEX AG and MediGene AG (EVT-DE, WL6-DE and MDG1-DE) that have also reported for this period. Highlights Summary numbers: Revenues of EUR 0.25 million, ... Read more (Read more...)
VNRX is required to contribute just $3M (paid in equal quarterly installments over 3 years), with most of the funding borne by the study's main sponsor, the U.S. National Cancer Institute's (NCI) Early Detection Network (EDRN), which is the leading cancer research organization in the U.S. The Great Lakes New England Clinical Validation Center and the University of Michigan are also major participants and, along with EDRN, focused on the pursuit of technologies for the early detection of cancer. • will include ~13.5k asymptomatic screening samples from subjects 50 years of age who have not previously undergone colonoscopy or CRC screening.